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We have previously reported that the synthetic estrogen, (+)-Z-bisdehydrodoisynolic Acid [(+)-Z-BDDA], attenuated weight gain
and cardiovascular risk in obese rodents. To determine if these antiobesity eﬀects were attributed to changes in basal metabolism,
we assessed indirect calorimetry and metabolic proﬁle in female obese Zucker (OZR) rats provided (+)-Z-BDDA (0.0002% food
admixture) for 11 weeks. Similar to our previous ﬁndings, (+)-Z-BDDA reduced weight gain and improved lipid and glucose
homeostasis in OZR rats. Furthermore, resting energy expenditure was increased by (+)-Z-BDDA, as evident by heat production
andoxygenconsumption.Wealsoobservedamarkedreductioninrespiratoryquotient(RQ)alongwithacorrespondinginduction
of hepatic AMPK in rodents provided (+)-Z-BDDA. Collectively, these ﬁndings indicate that (+)-Z-BDDA partially attenuated
obesity and associated pathologies through increased resting energy expenditure and fatty acid utilization. Further investigation is
requiredtofullyelucidate themechanisms involved aswell astodeterminethepotentialtherapeuticimplications for (+)-Z-BDDA
on obesity and its related pathologies.
1.Introduction
Doisynolic acids (DAs), such as (+)-Z-BDDA, are a group
of synthetically produced compounds that exhibit distinct
selective estrogen receptor modulator (SERM) activity in
vivo [1]. Based on the structural similarity to 17β-estradiol,
DAswereoriginallyinvestigatedasanalternativetohormone
replacement therapy [2, 3]. More recently, we demonstrated
that administration of these estrogenic compounds sup-
pressed weight gain in normal weight and obese rodents
[4–6]. In particular, IP injection of various BDDA isoforms
lowered body weight and total adiposity in Wistar and
Sprague-Dawley rats, independently of gender or energy
intake [5]. Similarly, (+)-Z-BDDA (0.0002% food admix-
ture) reduced weight gain and attenuated hyperglycemia
and dyslipidemia in female Zucker Diabetic Fatty (ZDF)
rats [4]. We also reported that (+)-Z-BDDA and related
compounds exhibited signiﬁcant cardiovascular protective
and antioxidant properties in several studies [4, 7]. However,
the speciﬁc mechanisms involved in the antiobesity eﬀects of
these compounds remain unclear.
Our previous studies showed a marked induction of
peroxisome-proliferator-activated receptor-α (PPARα)a n d
carnitine palmitoyltransferase-1 (CPT1) expression in liver
of obese rodents administered (+)-Z-BDDA [4]. The mod-
iﬁcation of these key regulators of fatty acid metabolism
is indicative of enhanced energy and substrate metabolism,
which may account for the suppression of weight gain and
prevention of obesity-related comorbidities. Thus, the objec-
tive of the current study was to determine how the synthetic
estrogen, (+)-Z-BDDA, impacts energy expenditure and
nutrient utilization in obesity. To achieve this, we evaluated2 Journal of Obesity
indirect calorimetry and metabolic proﬁle in female obese
Zucker (OZR) rats provided a 0.0002% food admixture of
(+)-Z-BDDA for 10 weeks.
2.MaterialandMethods
2.1. Animals. As previously described [4], (+)-Z-BDDA
prepared from (+)-Z-BDDA-3-OCH3 was administered to
female OZR (fa/fa) rats (4–6 weeks of age) as 0.0002%
food admixture. Animals were provided unlimited access to
semipuriﬁed diet (Table 1) with or without (+)-Z-BDDA for
11 weeks (n = 8). All experimental protocols for animal care
and use were approved by the Institutional Animal Care and
Use Committee.
Body weight and energy intake were measured weekly.
Nonfasted blood glucose (Glucometer Elite, Mishawaka, IN)
wasexaminedperiodicallytomonitorprogressionofdiabetic
phenotype (data not shown). Oral glucose tolerance test
(OGTT) was performed at week 10 following overnight fast
(8–10 hour) [8]. At termination, rats were fasted overnight,
euthanized by CO2 asphyxiation, and decapitated for col-
lection of trunk blood in heparinized tubes. Plasma was
utilized for quantitative determination of glucose, insulin,
cholesterol, and triacylglyceride (TAG) concentration [4].
Tissue was also immediately extracted, weighed, and frozen
for biochemical analysis.
2.2. Indirect Calorimetry. Assessment of 24-hour indirect
calorimetry (Accuscan Instruments Indirect Calorimeter,
Columbus, OH) was performed as previously described [9].
Brieﬂy, zirconia and infrared sensors were used to monitor
oxygen (O2) and carbon dioxide (CO2) inside respiratory
chambers.Allanimalswerestudiedsimultaneouslyusingdif-
ferent chambers connected to the same O2 and CO2 sensors.
After a 24-hour acclimation period, rats were monitored in
the metabolic chambers for 24 hours with unlimited access
to food and water. Gas samples were collected and analyzed
every 5 minutes per animal, and the data were averaged
for each hour. Output parameters included VO2 (L/d), RQ
(VCO2/VO2), and heat production (kJ/d).
2.3. Immunoblotting. Liver extracts were prepared and pro-
teins separated by SDS page as previously described [10].
The separated proteins were transferred to a nitrocellu-
lose membrane at 80V for 90min. Blots were blocked
overnight in 5% nonfat milk in tris-buﬀered saline with
0·05% Tween 20 (TBST) followed by incubation with
the speciﬁed primary antibody/antibodies for 2h (Santa
Cruz, CA, USA). After immunoblotting, membranes were
washed three times with TBST and incubated with the
appropriate secondary antibody conjugated with HRP for
another hour. After washing oﬀ excess secondary antibody,
blots were developed with SuperSignal West Pico Chemi-
luminescent Substrate (Thermo Scientiﬁc, Rockford, IL,
USA). X-ray ﬁlm densitometry was used for quantiﬁcation
(BioSpectrum Imaging System, Upland, CA, USA) and
signals measured with VisionWorksLS (UVP, Upland, CA,
USA).
Table 1: Composition of experimental diets.
Control (+)-Z-BDDA2
g/kg
Casein1 230 230
Sucrose 267.9 267.9
Cornstarch 310 310
Soybean oil 25 25
Lard 65 65
Cellulose1 50 50
Vitamin Mix1 10 10
Mineral Mix1 35 35
Choline Bitartrate1 2.5 2.5
DL-methionine 1.6 1.6
L-cysteine1 33
tert-butylhydroquinon1 .014 .014
(+)-Z-BDDA — .0018
1ICN Biomedicals, Irvine, CA.
20.00018% food add/mix of (+)-Z-BDDA.
Table 2: Metabolic parameters in female obese Zucker rats (n = 8)
provided (+)-Z-BDDA for 11 weeks.
Parameter Control (+)-Z-BDDA
Final Body WT (g) 447 ±20.5 390 ±34.0∗
Total WT Gain (g) 218 ±13.5 190 ±11.9∗
Total Energy Intake (kJ) 6351 ±493 5598 ±547
L i v e rw t( %B o d yW T ) 6 .40 ±0.15 5.30 ±0.36∗
OGTT AUC (Arbitrary
Units) 632 ±61.5 444 ±66.1∗
Plasma Insulin (nmol/L) 1.21 ±0.19 0.91 ±0.03
Plasma Triglycerides
(mmol/L) 4.24 ±0.51 3.69 ±1.27
Plasma Cholesterol
(mmol/L) 7.02 ±0.79 3.12 ±0.41∗
∗indicates signiﬁcant reduction by (+)-Z-BDDA treatment compared to
control as determined by Student’s t-test (P<0.05).
2.4. Statistical Analysis. Data are presented as means ±
SE, compared by Student’s t-test (SYSTAT7 10.0, SPSS
I n c o r p o r a t e d ,C h i c a g o ,I L ) .
3. Results
Consistent with our previous work [4, 5], (+)-Z-BDDA
reduced body weight and total weight gain, independent of
energy intake (Table 2, P<0.05). These eﬀects corresponded
with an improved metabolic phenotype in female OZR rats.
In particular, liver weight and plasma total cholesterol were
reduced by 18% and 56% in (+)-Z-BDDA-treated animals
(Table 2, P<0.05), respectively. In addition, oral glucose
tolerance was improved by approximately 30% with (+)-Z-
BDDA treatment. Although we did not detect improvements
in plasma insulin or TAG concentration (Table 2), these
data conﬁrm that (+)-Z-BDDA administration partiallyJournal of Obesity 3
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Figure 1: (+)-Z-BDDA enhanced basal metabolism and fatty acid oxidation in female OZR rats. After a 24-hour acclimation period, rats
were monitored in the metabolic chambers (Accuscan Instruments Indirect Calorimeter, Columbus, OH) for 24h with unlimited access to
food and water. Gas samples were collected and analyzed every 5 minutes, averaged for each hour, and presented as total for 24h period.
Output parameters included heat production (kJ/d), VO2 (L/d), and RQ (VCO2/VO2). All measures were obtained from female OZR rats
after 11 weeks of (+)-Z-BDDA treatment (n = 8). Graphed values represent means ± SE. Asterisks (∗) represent signiﬁcant diﬀerences
among means as determined by Student’s t-test (P<0.05). (a) Heat production expressed as kilojoules per day; (b) oxygen consumption
expressed as liters per day; (c) respiratory quotient (RQ).
attenuates obesity-related comorbidities through reduced
weight gain.
Using 24-hour indirect calorimetry, we then examined if
changes in basal metabolism and substrate utilization were
responsible for the antiobesity properties of (+)-Z-BDDA.
Here, we observed that heat production (Figure 1(a))a n d
oxygen consumption (Figure 1(b)) for both light and dark
cycles were approximately 60% greater with (+)-Z-BDDA
treatment when adjusted for dietary intake (P<0.05).
Furthermore,wedetectedmarkedlylowerRQvaluesinobese
rodents provided (+)-Z-BDDA (Figure 1(c), P<0.05).
These data indicate that (+)-Z-BDDA enhanced resting
energy expenditure and fatty acid utilization, which likely
contributed to improvements in obesity phenotype.
Our previous work [4] has shown that PPARα and CPT1
expression—key regulators of fatty acid oxidation—were
induced in liver by (+)-Z-BDDA treatment. To determine if
enhanced fatty acid oxidation in liver might contribute to
changes in energy expenditure, we measured activation of
AMPK, an upstream regulator of fatty acid oxidation. From
this analysis, we identiﬁed a nearly 40% induction of hepatic
AMPK phosphorylation in (+)-Z-BDDA-treated OZR rats4 Journal of Obesity
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Figure 2: (+)-Z-BDDA enhanced hepatic AMPK phosphorylation in female OZR rats. Liver extracts were prepared and proteins separated
by SDS page as previously described [10]. Following incubation with primary and secondary antibodies (Santa Cruz), immunoblots were
developedwithSuperSignalWestPicoChemiluminescentSubstrate(ThermoScientiﬁc).X-rayﬁlmdensitometrywasusedforquantiﬁcation
(BioSpectrum Imaging System) and analysis (VisionWorksLS, UVP). All measures were obtained from female OZR rats after 11 weeks of
(+)-Z-BDDA treatment (n = 4). (a) Hepatic AMPK phosphorylation (AMPK1/2 Thr172), total AMPK (AMPKα1/2 H-300), and CD36 (H-
300) are presented as representative blots from control and (+)-Z-BDDA groups; (b) all displayed values represent percentage of control
(means ± SE). Signiﬁcant diﬀerences between groups were determined by Student’s t-test (P<0.05) and indicated by asterisk (∗).
(Figure 2,P<0.05),whichoccurredwithoutchangesintotal
AMPK (Figure 2). Thus, the antiobesity properties of (+)-Z-
BDDA may partially reﬂect enhanced fatty acid in liver.
4. Discussion
In this study, we conﬁrmed earlier ﬁndings [4–6] that (+)-
Z-BDDA reduced weight gain, independently of energy
intake. Similarly, female Zucker diabetic fatty (ZDF) rats
administered (+)-Z-BDDA for six months had lower body
weight, total adiposity, and enhanced physiological and
cardiovascular function [4]. Here, we observed an improve-
ment in lipid and glucose homeostasis with (+)-Z-BDDA
treatment (Table 1). The augmentation of these metabolic
parameters may be attributed to lower body weight and
total adiposity. Additionally, (+)-Z-BDDA may attenuate the
development of obesity-related pathologies independently of
weight gain. For instance, estrogenic compounds have been
reported to reduce inﬂammation in obese postmenopausal
women without changes in body weight [11, 12]. The direct
impact of (+)-Z-BDDA and related compounds on these
comorbidities should be addressed in future studies. In
particular, the eﬃcacy of (+)-Z-BDDA should be compared
to natural estrogens. Our previous work with soy phytoe-
strogens (i.e., genistein and daidzein) has shown signiﬁcant
hepatoprotective properties in vivo [13, 14]. Thus, it is
possible that these compounds share a similar signaling
mechanismthatresultsinchangestoenergyexpenditureand
substrate utilization.
Obese rodents typically exhibit lower heat production
and oxygen consumption compared to lean counterparts
[15]. For this study, we demonstrated that (+)-Z-BDDA
treatment reduced this eﬀect and enhanced resting energy
expenditure in female OZR rats. These eﬀects were even
more apparent after normalization of heat production
and oxygen consumption for dietary intake. This was an
important adjustment as heat increment can be consid-
erably inﬂuenced by diﬀerences in energy consumption
[16]. In addition to changes in basal energy expenditure,
we observed markedly lower RQ values with (+)-Z-BDDA
treatment. Although implementation of RQ as a marker
of fatty acid oxidation is not ideal [17], these values are
consistent with enhanced fat oxidation. However, the impact
of (+)-Z-BDDA on fatty acid utilization in obesity will
need to be clariﬁed by further analysis (i.e., non-protein
RQ).
We previously demonstrated that (+)-Z-BDDA induced
expression of PPARα and CPT1 in liver of female ZDF rats
[4]. Based on these ﬁndings, we measured phosphorylation
of AMPK—a master regulator of fatty acid metabolism in
liver. Here, we observed a marked increase in hepatic AMPK
phosphorylation with (+)-Z-BDDA treatment. Although
this is not a direct measure of fatty acid oxidation, the
data are consistent with an induction of mitochondrial fatty
oxidation. In the current study, we did not examine the
potential involvement of extrahepatic tissues in regulation
of these mechanisms. In particular, 17β-estradiol is reported
to directly stimulate AMPK phosphorylation in primary
muscle cells [18]. To address these limitations, we are
currently working with primary hepatocytes and myotubes
to determine how (+)-Z-BDDA modiﬁes energy and fatty
acid metabolism in these tissues. Moreover, future in vivoJournal of Obesity 5
experimentsneedtoincorporateadditionalmeasurementsof
AMPK induction, including the ATP to ADP ratio.
Collectively, these data—along with previous work [4,
5]—support a potential therapeutic role for (+)-Z-BDDA
in the prevention of obesity and its related comorbidities.
Furthermore, we have identiﬁed that the antiobesity eﬀects
of (+)-Z-BDDA are partially mediated through enhanced
resting energy expenditure and fatty acid utilization. Future
work will need to address the speciﬁc cellular targets
and mechanisms involved with these metabolic eﬀects, as
well as identify the potential for (+)-Z-BDDA and related
compounds to be used as weight loss agents.
5. Conclusions
These ﬁndings indicate that the synthetic estrogen, (+)-Z-
BDDApartiallyattenuatedobesityanditsrelatedpathologies
through enhancement of resting energy expenditure and
fatty acid utilization. Further investigation is required to
identify the speciﬁc molecular targets of these compounds as
well as to determine their potential therapeutic implications
in humans.
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